14 October 2020 | News
F4 Pharma is collating world-leading clinicians and scientists to support further clinical development of FX06 in diseases caused by endothelial dysfunction
Photo Credit: Freepik
After encouraging results obtained under named patient use in severe cases of COVID-19, F4 Pharma is now preparing clinical trials in several European centers with its substance FX06.
There is emerging evidence that severe COVID-19 affects all organs through a systemic inflammation of the inner layer of the small blood vessels leading to increased permeability of the capillaries, which can finally result in multi-organ failure and death. The dysfunctional endothelium is the link between the pathological pathways of inflammation and coagulation observed in patients with severe COVID-19 and explains the clinical manifestations like thrombosis and disturbed microcirculation. FX06 is able to interrupt this vicious circle by interfering with the inflammatory process, thereby reducing the capillary leak and improving patient outcome.
But severe COVID-19 is not the only disease associated with capillary leak and inflammation. The same pathomechanism can be observed in multiple life-threatening diseases and is regarded as a major complication in intensive care. Therefore, a positive outcome in severely affected COVID-19 patients will serve as the starting point for the clinical development of FX06 in other diseases with a high unmet medical need.
In order to help F4 Pharma’s to advance FX06 and to provide strategic guidance, F4 Pharma has appointed a scientific advisory board consisting of world-leading clinicians and scientists.
The scientific advisory board is led by Prof. Kai Zacharowski in association with 8 other experts.